Long-term follow-up for patients with hemoglobin disorders after transplant or gene therapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to monitor individuals with hemoglobin disorders who have undergone allogeneic hematopoietic stem cell transplantation or received autologous genetically modified cellular products. It focuses on assessing the long-term effects and potential adverse outcomes of these treatments in accordance with FDA guidelines. Participants will be routinely evaluated to gather data on their health status and any complications that may arise over time.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Receipt, or planned receipt, of an allogeneic HSCT or infusion of genetically modified autologous cells for hemoglobin disorders within 15 years prior to enrollment

Exclusion Criteria:

* Inability or unwillingness of research participant and/or legal guardian/ representative to provide written informed consent.

Where it's running

• St. Jude Children's Research Hospital
  Memphis, Tennessee, United States Recruiting

Study contacts

• Principal investigator: Akshay Sharma, MD — St. Jude Children's Research Hospital
• Study coordinator: Akshay Sharma, MD
• Email: referralinfo@stjude.org
• Phone: 8662785833

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Integrated diagnosis for sickle cell disease and other rare anemias

  This project tests whether combining genetic testing, LoRRca ektacytometry, and microfluidic analysis can improve diagnosis and predict disease course for people with sickle cell disease and other inherited anemias.

  Recruiting at 4 sites Hospital Universitari Vall d'Hebron Research Institute · Barcelona and 3 other locations · NCT07206095

• 131I-apamistamab conditioning for stem cell transplant in advanced sickle cell disease

  This trial tries to see if a targeted radioactive antibody (131I-apamistamab) can be used as the pre-transplant conditioning to prepare people aged 12–50 with advanced sickle cell disease and an HLA-matched sibling donor for an allogeneic stem cell transplant.

  Recruiting Phase 1 Columbia University · New York, New York · NCT07015684

• Haploidentical stem cell transplantation for sickle cell disease

  This study is testing a new type of stem cell transplant for people with sickle cell disease to see if it can cure the disease while causing fewer complications.

  Recruiting at 4 sites Phase 2 University of Regensburg · Vienna and 8 other locations · NCT04201210

• Transfusion-Related Changes in Oxidative Stress Markers in Newborns

  This study tests whether red blood cell transfusions and oxygen therapy affect oxidative stress markers in newborns, especially extremely preterm babies.

  Recruiting Medical University of Graz · Graz, Styria · NCT07672275

• Investigating thalidomide's effects on beta thalassemia

  This study is testing whether low doses of thalidomide can help young people with beta thalassemia manage their condition better and reduce the need for blood transfusions.

  Recruiting Phase 2 National Institute of Blood and Marrow Transplant (NIBMT), Pakistan · Karachi, Sindh · NCT06490627

• T cell receptor depletion for blood cancer treatment

  This study is testing a new way to treat blood cancers by using a special treatment before a stem cell transplant to see if it helps both kids and adults do better after the procedure.

  Recruiting Phase 2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT05735717

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.